About Armune
Armune is a Healthcare company based in Kalamazoo (United States) founded in 2008, and was acquired by Exact Sciences in February 2018. Diagnostic tests for prostate, lung, and breast cancers are developed. Armune has raised $12.21 million across 10 funding rounds from investors including Exact Sciences, University of Michigan and Grand Angels. The company was acqui-hired. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Guardant Health, Foundation Medicine and ArcherDX; 3 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2008 and is located in Kalamazoo, United States, within the biotechnology sector. Diagnostic and prognostic tests for prostate, lung, and breast cancers are researched and developed to support personalized treatment decisions. These tests rely on immune system signals for early detection and improved outcomes. A validated blood test, APIFINY, is provided for prostate cancer screening as a non-PSA alternative, enabling biopsy selection for patients.
- Headquarters Kalamazoo, United States
- Stage Acquired
- SectorsHealthcare
- Website armune.com
- Social LinkedIn X Facebook
- Acquired by Exact Sciences (Feb 2018)
- Total Equity Funding$12.21M (USD)
in 10 rounds
- Latest Funding Round$500K (USD), Series A
Jan 2017
- InvestorsExact Sciences
& 5 more
- Acquired byExact Sciences
(Feb 2018)
Funding Insights of Armune
Armune has successfully raised a total of $12.21M across 10 strategic funding rounds. The most recent funding activity was a Series A round of $500 thousand completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.21M
- Total Rounds 10
- Last Round Series A — $500,000
- First Round $1.1M
(Sep 2008)
- Investors Count 5
All 10 funding rounds of Armune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $500,000 | Series A | – | – | – |
| Jul 2016 | $9.71M | Series A | – | University of Michigan, Grand Angels | – |
| Apr 2013 | $1.4M | Seed | – | – | – |
| Nov 2012 | $19,217 | Grant | – | – | |
| Dec 2010 | $250,000 | Debt – Conventional | – | – | – |
| Dec 2010 | $500,000 | Grant | – | – | |
| Jun 2010 | Seed | – | – | ||
| Aug 2009 | $400,000 | Seed | – | – | – |
| Dec 2008 | $200,000 | Seed | – | – | |
| Sep 2008 | $1.1M | Debt – Convertible | – | – | – |
6 investors in total: 6 institutional.
Investors in Armune
Armune has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Exact Sciences, University of Michigan and Grand Angels.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Grand Angels is engaged in angel investing for startups. | 2005 | grandangels.org | Grand Rapids, United States | |
| acceleratemichigan.com | ||||
| annarborusa.org | ||||
Graduation and postgraduate courses are offered in diverse academic streams. | 1817 | umich.edu | United States | |
A digital news platform is operated for diverse topics. | michigancrn.org | Jakarta, Indonesia | ||
Non-invasive molecular diagnostic tests for cancer detection are provided. | 1995 | exactsciences.com | Madison, United States |
Investor details for Armune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Armune
4 dated milestones of Armune across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Armune is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Series A, of $500K.
- Exit Acquired by Exact Sciences.
Competitors of Armune
Armune has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Foundation Medicine and ArcherDX.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. |
Detailed competitors of Armune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Armune (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Armune
Armune was founded in 2008.
Armune is headquartered in Kalamazoo, United States. It is registered at Kalamazoo, Michigan, United States.
Armune is a funded company, having raised a total of $12.21M across 10 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $1.1M, raised on Sep 2008.
The company was founded in 2008 and is located in Kalamazoo, United States, within the biotechnology sector. Diagnostic and prognostic tests for prostate, lung, and breast cancers are researched and developed to support personalized treatment decisions. These tests rely on immune system signals for early detection and improved outcomes. A validated blood test, APIFINY, is provided for prostate cancer screening as a non-PSA alternative, enabling biopsy selection for patients.
Armune's top competitors include Guardant Health, Foundation Medicine and ArcherDX.
Armune has 6 investors. Key investors include Exact Sciences, University of Michigan, Grand Angels, Michigancrn, and Accelerate Michigan.
Yes. Armune was acquired by Exact Sciences in February 2018.